[<sup>177</sup>Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study

May 22, 2018

[<sup>177</sup>Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study

Published on 05/21/2018

previous post: Effect of paracetamol/prednisolone vs paracetamol/ibuprofen on post-operative recovery after adult tonsillectomy
next post: Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease